Expression of cyclooxygenase-1 and -2 in human colorectal cancer - PubMed (original) (raw)

. 1995 Sep 1;55(17):3785-9.

Affiliations

PMID: 7641194

Expression of cyclooxygenase-1 and -2 in human colorectal cancer

H Sano et al. Cancer Res. 1995.

Abstract

Several studies indicate that nonsteroidal anti-inflammatory drugs including indomethacin, aspirin, sulindac, and piroxicam reduce the risk of colon cancer. Furthermore, nonsteroidal anti-inflammatory drugs that inhibit the cyclooxygenase (COX) enzyme were shown to inhibit the development of colon cancer in animal models of carcinogenesis. Non-steroidal anti-inflammatory drugs inhibit the enzymatic activity of both the constitutive (COX-1) and inducible (COX-2) isoforms of COX enzyme. We have investigated the expression of COX-1 and COX-2 polypeptides in human colon cancer tissues using immunohistochemistry. Enhanced COX-2 expression was observed in colon cancer tissues from 15 subjects with clinically diagnosed colorectal cancer. Marked COX-2 expression was observed in cancer cells, inflammatory cells, vascular endothelium, and fibroblasts of the lesional tissues compared with the nonlesional and normal colon tissues. The extent and intensity of the immunoreactive COX-2 in cancer cells was much greater than that of the other cell types. In contrast, the expression of COX-1 polypeptide was weak in both normal and cancerous specimens. These data suggest that the enhanced expression of the COX-2 gene in colon cancer tissues may contribute to the enhanced synthesis of prostaglandin E2 by the colon cancer tissues. Enhanced expression of COX-2 may play a role in the pathogenesis of colon cancer. Furthermore, selective inhibition of COX-2 may prove to be more efficacious in the retardation of colon cancer development.

PubMed Disclaimer

Cited by

Aspirin Prevents Colorectal Cancer by Normalizing EGFR Expression.
Li H, Zhu F, Boardman LA, Wang L, Oi N, Liu K, Li X, Fu Y, Limburg PJ, Bode AM, Dong Z. Li H, et al. EBioMedicine. 2015 May 1;2(5):447-455. doi: 10.1016/j.ebiom.2015.03.019. EBioMedicine. 2015. PMID: 26097892 Free PMC article.
Potential use of COX-2-aromatase inhibitor combinations in breast cancer.
Bundred NJ, Barnes NL. Bundred NJ, et al. Br J Cancer. 2005 Aug;93 Suppl 1(Suppl 1):S10-5. doi: 10.1038/sj.bjc.6602690. Br J Cancer. 2005. PMID: 16100520 Free PMC article. Review.
Effects of transforming growth factor-beta in the development of inflammatory pseudotumour-like lesions in a murine model.
Guariniello LD, Correa M, Jasiulionis MG, Machado J Jr, Silva JA Jr, Pesquero JB, Carneiro CR. Guariniello LD, et al. Int J Exp Pathol. 2006 Jun;87(3):185-95. doi: 10.1111/j.1365-2613.2006.00471.x. Int J Exp Pathol. 2006. PMID: 16709227 Free PMC article.
COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ.
Boland GP, Butt IS, Prasad R, Knox WF, Bundred NJ. Boland GP, et al. Br J Cancer. 2004 Jan 26;90(2):423-9. doi: 10.1038/sj.bjc.6601534. Br J Cancer. 2004. PMID: 14735188 Free PMC article.
RNA profiling of cyclooxygenases 1 and 2 in colorectal cancer.
Church RD, Yu J, Fleshman JW, Shannon WD, Govindan R, McLeod HL. Church RD, et al. Br J Cancer. 2004 Sep 13;91(6):1015-8. doi: 10.1038/sj.bjc.6602119. Br J Cancer. 2004. PMID: 15328521 Free PMC article.

Expression of cyclooxygenase-1 and -2 in human colorectal cancer - PubMed (original) (raw)